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26* 25 Years newborn screening programme suggests a changing
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Background: Screening of CF in NZ commenced June 1981 as a pilot programme
and has been continous from January 1983. A positive screen was based on two
high immunoreactive trypsin (IRT) results. From July 1996 the presence of 1 or 2
positive genes replaced the second IRT.
Aims: To determine the number of positive, carrier and missed cases of CF and to
determine the incidence of CF over 25 years of screening.
Method: We reviewed National Testing Centre records 1983–2007, and reviewed
the results recorded on the audit sheet sent out with all positive screen results
and compared these to our known CF clinical database. Population statistics were
obtained from Census data 1996 and 2006.
Results: From 1983 to 2007 there were 2,260,747 infants screened with 306
cases of CF detected and 26 cases missed. From 1997 to 2007 (genetic screening
added) the mean sensitivity was 97.5% (range 88–100), mean speciﬁcity 99.92%
( 99.94–99.87), mean positive predictive value 21.67 (21.95–20.78). Audit forms
are completed 100% to 2000 with some missing from 2001 to 2007. In Auckland
(1/3 of population, 100% audit form returns) the incidence of CF has changed from
1/3852 in 1997 to 1/6652 in 2006. From Census data, in 1997 the population of
Auckland was 63% European, 9.8% Maori, 12.9% Paciﬁc, 13.4 Asian/other and
in 2006 the population was 56.5% European, 11.1% Maori, 14.4% Paciﬁc, 18.9%
Asian/other.
Conclusion: The newborn screening programme has good sensitivity and speci-
ﬁcity. The incidence of CF is changing in Auckland and possibly NZ due to
broadening ethnic diversity of the population but missing national audit responses
needs to be assiduously followed up to conﬁrm this.
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Castilla-Leo´n introduced newborn screening for Cystic Fibrosis (CF) in March
1999, being the ﬁrst spanish region doing it. This study included all the neonates
screened in Castilla-Leon from March 1, 1999, to Dec 31, 2010. The screening
consisted of an immunoreactive trypsinogen assay from dried blood followed for
analysis of the 84% of the CF causing mutations in our population. Samples
with an IRT level higher than 70 ng/mL (cut-off) are sistematically analised for
F508del/I507del mutation (exon10) by PAGE of the PCR product and mutations
in exons 7, 11, 12, 14b and 17b by DGGE method followed by direct sequencing
of abnormal patterns. DNA is obtained from the bloodspot by Chelex 100 and
informed consent for genetic screening is previously obtained. Sweat test is carried
out in neonates bearing ad least one mutation.
Results: We have screened 225,814 newborns, 1763 with increased IRT (0.78%).
Fourthy ﬁve of them were diagnosed as CF (1 or 2 CF mutations in trans + positive
sweat test), giving an incidence of 1/5018. More than 96% (87/90) of mutant alleles
were characterised (two of the 3 remaining CF alleles were genotyped in other
centres and the other one remains unknown). Eighteen different mutations resulting
in 21 different genotypes were identiﬁed: 19/45 (42.2%) homozygotes F508del and
18/45 (40%) were F508del heterozygotes. There have found also 110 carriers with
a high proportion of mild mutations (G576A). Up to now, no false negatives have
been reported.
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Objectives: The aim − to analyze the frequency of CFTR mutations among
hypertrypsinogenemic newborns (IRT I) detected during neonatal screening in 2008,
and represent a risk group for CF. In this group we plan to calculate the frequency
of CF affected, carriers and noncarriers of CFTR-mutations and to calculate the
relative CF risk in newborns with a positive IRT test results (IRT I, IRT II).
Methods: Samples of dried blood spots from 380 newborn babies with ﬁrst positive
IRT test were investigated for eight CFTR mutations: F508del, CFTRdele2,3(21kb),
3821delT, 1677delTA, I507del, 2143delT, 2184insA, 394delTT, sharing 67.5% of
all mutant alleles in CF patients in Russian population.
Results: In 11 out of 380 individuals were identiﬁed CFTR mutations in the
heterozygous condition: F508del − in 8 cases, CFTRdele2,3(21kb) − in 2 samples,
3821delT − in 1 sample. The frequency of CFTR identiﬁed mutations in a group
newborn babies tested positive for the ﬁrst IRT is 0.0115, that is signiﬁcantly higher
than the population frequency of these mutations (0.0064), as deﬁned previously
(c2=4.79; d.f.=1; p = 0.0028). All 11 newborn children from CF risk group were
retested for IRT II, according to the accepted scheme. Only two (18%) were noted
by increased IRT retest (>40 ng/ml: 75 ng/ml and 47 ng/ml). Repeated sweat tests
were carried out in both cases. Test’s results were negative and the diagnosis of CF
was excluded.
Conclusion:We can not exclude the inﬂuence of heterozygous carrier of CFTR mu-
tations (F508del, CFTRdele2,3(21kb), 3821delT) on enhance of IRT concentration,
as a consequence of functional insufﬁciency of the pancreas in the newborn.
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Aims: Parental views of the service provision for newborn screening (NBS) for CF
in the West Midlands, UK was evaluated 2 years after NBS started in November
2006.
Methods and Results: Parents of children identiﬁed as positive or false positive
through the screening programme, were invited to complete a questionnaire con-
taining quantitative and qualitative questions.18 out of a possible 39 responded.
53% of parents were unaware when they became pregnant that their child would
be screened for CF. 21% of babies required a 2nd heel prick test, for which 75%
felt the reason was not clearly explained. 89% were happy to be told the screening
outcome/result by a visit, as happened, 11% would have preferred a telephone call.
73% felt that the screening nurse specialist was the most appropriate person to
make the visit, others preferring to have someone present who they already knew.
The paediatrician and CF nurse were present at the hospital visit for the majority
of appointments and were found to be very important. At this visit, 93% were
informed their child had CF, 100% were told about CF and the genetics, 94% were
given enough time to ask questions. 88% felt the information about CF was enough
and 12% felt it was too much.100% were informed what treatment was required and
had time to ask questions about treatment, 95% felt the information about treatment
was enough, 5% felt it was too much. In general 94% felt that the support they
received from the CF team was about right and 6% felt that there wasn’t enough
support.
Conclusion: Parents of children who went through the NBS programme were
overall very satisﬁed with the service and the support they received from the CF
team.
